Abstract: A carbohydrate composition includes fucose, glucuronic acid, galactose, and arabinose. Based on the total weight of the carbohydrate composition, the content of fucose is 45.5% to 76% by weight; the content of glucuronic acid is 11% to 19% by weight; the content of galactose is 4.5% to 14.5% by weight, and the content of arabinose is 5.5% to 18% by weight. A pharmaceutical ingredient including the above-mentioned carbohydrate composition is provided.

Abstract: A method for enhancing wound healing or treating methicillin-resistant Staphylococcus aureus (MRSA) infection in a wound comprising administering a subject in need thereof with a therapeutically effective amount of a tilapia piscidin (TP) is described, wherein the TP is preferably TP3 or TP4.

Abstract: The preset invention relates to a new method or composition for treating a gastric ulcer, preventing or treating an infection of H. pylori, particularly multidrug resistant H. pylori, using an antimicrobial peptide, a functional derivate, fragment or variant thereof, wherein the antimicrobial peptide is selected from the group consisting of Epi-1, TPs and combination thereof.

Abstract: The preset invention relates to a new method for wound healing, particularly in burns, comprising Epinecidin-1 (Epi-1) or Pardaxin (GE33), optionally in the incorporation into collagen.

Abstract: The preset invention relates to a new method for enhancing wound healing comprising administering a subject in need thereof with a therapeutically effective amount of a tilapia piscidin (TP), which is selected from the group consisting of TP1, TP2, TP3, TP4, TP5 and combination thereof. A composition or pharmaceutical composition comprising the TP are also provided.

Abstract: The preset invention relates to a new method or composition for treating a gastric ulcer, preventing or treating an infection of H. pylori, particularly multidrug resistant H. pylori, using an antimicrobial peptide, a functional derivate, fragment or variant thereof, wherein the antimicrobial peptide is selected from the group consisting of Epi-1, TPs and combination thereof.

Abstract: The preset invention relates to a new method for wound healing, particularly in burns, comprising Epinecidin-1 (Epi-1) or Pardaxin (GE33), optionally in the incorporation into collagen.

Abstract: The present invention discloses a physical nano-complex for preventing and treating cancer and a method for manufacturing the same. The composition contains EGCG and nanogold, wherein the ratio of the EGCG to the nanogold is in a range from 23:0.5˜23:10 (ppm/ppm). The present invention further discloses a method for manufacturing the composition, wherein the method is to mix the EGCG and the nanogold sufficiently by an ultrasonication process, which makes the EGCG and the nanogold combine to each other well.

Abstract: A transportation device, physically transporting material to a target, includes an input module, a transporting module and an output module. The input module provides a carrier fluid. The transporting module is coupled to the input module for receiving the carrier fluid in order to disperse/atomize the material. The material enters the input module through a first opening and reaches the target Through a second opening. The input module further includes a guiding unit having a length longer than or equal to the distance between the throat portion and the second opening. One end of the guiding unit connects the transporting module. The other end of the guiding unit has a guiding comer for connecting to the first opening.

Abstract: The present invention discloses a physical nano-complex for preventing and treating cancer and a method for manufacturing the same. The composition contains EGCG and nanogold, wherein the ratio of the EGCG to the nanogold is in a range from 23:0.5˜23:10 (ppm/ppm). The present invention further discloses a method for manufacturing the composition, wherein the method is to mix the EGCG and the nanogold sufficiently by an ultrasonication process, which makes the EGCG and the nanogold combine to each other well.

Abstract: A method of enhancing a mammalian immune response to a virus is disclosed. The method comprises administering a composition comprising an effective amount of epinecidin (Epi)-1 and the virus to a mammal, wherein the virus has envelope protein and is infectious to the mammal. A vaccine kit and a method for preventing Japanese encephalitis virus (JEV) infection are also disclosed.

Abstract: The present invention relates to a method for monitoring and recording a viral infection process, which is characterized by providing a microcantilever detection device, which comprises a microcantilever comprising a contact area having an macromolecular material attached thereon; loading host cells to the contact area to allow the host cells to be attached to the macromolecular material; loading virus to the contact area to make the virus to contact the host cells attached thereto whereby a deflection level of the microcantilever is produced; and recording the deflection level in a time course manner so as to obtain a deflection curve that can be used as a basis for monitoring and recording the viral infection process. The method of the invention can also be used for screen for an agent that inhibits virus infection.

Abstract: A method of enhancing a mammalian immune response to a virus is disclosed. The method comprises administering a composition comprising an effective amount of epinecidin (Epi)-1 and the virus to a mammal, wherein the virus has envelope protein and is infectious to the mammal. A vaccine kit and a method for preventing Japanese encephalitis virus (JEV) infection are also disclosed.

Abstract: The present invention relates to a method and system for monitoring and recording a viral infection process and that for screening vaccines, which is characterized by providing a microcantilever detection device, which comprises a microcantilever comprising a contact area having an macromolecular material attached thereon; allowing host cell to be attached to the macromolecular material; allowing a sample containing a test virus or vaccine to be loaded into the contact area to make the test virus or vaccine to contact the host cells attached to the macromolecular material so as to produce a deflection of the microcantilever; and recording the deflection in a time course manner so as to obtain a deflection profile that can used as a basis for determining the viral infection process or the potential efficacy of the vaccines.

Abstract: This invention relates to a DNA vaccine preparation in a patch against virus infection comprising a DNA construct incorporated in a liposome, wherein the ratio of DNA to liposome is from 1:1 to 1:10; wherein the DNA vaccine preparation is preferably administrated after a pretreatment with alpha hydroxyl acids.

Abstract: A transportation device, physically transporting a material to a target, includes an input module, a transporting module and an output module. The input module provides a carrier fluid. The transporting module is coupled to the input module for receiving the carrier fluid in order to disperse/atomize the material. The output module has a throat portion, a first opening and a second opening. The throat portion is positioned between the first opening and the second opening, and the aperture of the first opening is larger than that of the second opening. The distance between the throat portion and the second opening is equal to or smaller than the distance between the throat portion and the first opening and is between three and ten times of the throat portion aperture (d). The second opening has an expending angle which is between half and three times of the throat portion aperture angle) (½d°-3d°. The material enters the input module through the first opening and reaches the target through the second opening.

Abstract: The invention relates to chitosan (CS) vehicles with chitosan nanoparticles, as well as methods for making such chitosan vehicles and for using them to carry a DNA or proteins by forming CS-DNA or CS-protein complexes. The present invention also relates to CS-DNA or CS-protein complexes being useful for transdermal delivery of DNA or protein with a low-pressure gene gun. In another aspect, the present invention also relates to CS-DNA or CS-protein complexes being useful for transcutaneous delivery of a DNA or protein with a skin patch. Further aspects of the present invention relate to methods for making CS-DNA or CS-protein complexes and for using them for diagnostic, therapeutic and biological industrial applications.

Abstract: A DNA vaccine of Japanese encephalitis virus (JEV) of the present invention comprises at least one vector encoding a membrane protein and an envelope protein gene of JEV. Furthermore, the DNA vaccine contains a cytomegalovirus early promoter sequence, an enhancer sequence, a chimeric intron, a bovine growth hormone polyadenylation sequence and a kanamycin resistant gene. The DNA vaccine can enhance antigentic stability and provide a high level of immunity.

Abstract: The present invention provides a method of treating cancer in a mammal comprising delivering by electroporation an immunocytokine or cytokine gene in an expression plasmid into cells of the mammal.